Genomed EV/FCF

Mitä Genomed tekee? Genomed SA is a biotechnology company headquartered in Warsaw, Poland, operating within the Health Care sector. The company went public on May 30, 2011, with its ticker listed as GEN.WA and ISIN PLGNOMD00024. Genomed SA specializes in medical diagnostic services, particularly focusing on molecular diagnostics using DNA sequencing technology. The company emphasizes Next Generation Sequencing (NGS) methods for its diagnostic offerings. Its services include analysis of gene mutations linked to over 150 congenital diseases, such as infertility, cancer predisposition, cystic fibrosis, Alzheimer's disease, hearing loss, coeliac disease, cardiomyopathy, and obesity. The company aims to integrate genomic technology into personalized medicine and has developed a clinic dedicated to gene treatments. Additionally, Genomed SA provides DNA sequencing, analysis, and synthesis services for research and biotechnology industry clients. The company's website is http://www.genomed.pl/, and it operates primarily in the Mazowieckie region of Poland. Genomed SA's business model centers on leveraging genomic data to improve diagnostic accuracy and support tailored medical interventions. Its focus on NGS technology positions it as a provider of advanced diagnostic solutions within the biotechnology sector. The company's activities reflect a commitment to expanding the application of genomics in clinical settings, particularly for inherited conditions and chronic diseases. Genomed SA's services are designed to assist healthcare providers in making more informed decisions through genetic insights. The firm continues to develop its capabilities in genomic analysis to meet evolving healthcare demands. Genomed on yksi Eurpooliin suosituimmista yhtiöistä.